These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18414469)

  • 1. A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.
    Siegel-Lakhai WS; Zandvliet AS; Huitema AD; Tibben MM; Milano G; Girre V; Diéras V; King A; Richmond E; Wanders J; Beijnen JH; Schellens JH
    Br J Cancer; 2008 Apr; 98(8):1320-6. PubMed ID: 18414469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.
    Zandvliet AS; Siegel-Lakhai WS; Beijnen JH; Copalu W; Etienne-Grimaldi MC; Milano G; Schellens JH; Huitema AD
    Clin Pharmacol Ther; 2008 Jun; 83(6):829-39. PubMed ID: 17851564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
    Deenen MJ; Klümpen HJ; Richel DJ; Sparidans RW; Weterman MJ; Beijnen JH; Schellens JH; Wilmink JW
    Invest New Drugs; 2012 Aug; 30(4):1557-65. PubMed ID: 21809026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
    Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
    Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.
    Dugan E; Truax R; Meadows KL; Nixon AB; Petros WP; Favaro J; Fernando NH; Morse MA; Blobe GC; Hurwitz HI
    Anticancer Res; 2010 Apr; 30(4):1251-6. PubMed ID: 20530436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
    Awada A; Gil T; Whenham N; Van Hamme J; Besse-Hammer T; Brendel E; Delesen H; Joosten MC; Lathia CD; Loembé BA; Piccart-Ghebart M; Hendlisz A
    J Clin Pharmacol; 2011 Dec; 51(12):1674-84. PubMed ID: 21209247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I and pharmacokinetic study of indisulam in combination with carboplatin.
    Dittrich C; Zandvliet AS; Gneist M; Huitema AD; King AA; Wanders J
    Br J Cancer; 2007 Feb; 96(4):559-66. PubMed ID: 17285128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
    Sayar H; Shen Z; Lee SJ; Royce M; Rabinowitz I; Lee F; Smith H; Eberhardt S; Maestas A; Lu H; Verschraegen C
    Invest New Drugs; 2009 Apr; 27(2):153-8. PubMed ID: 18773144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.
    Chu QS; Schwartz G; de Bono J; Smith DA; Koch KM; Versola MJ; Pandite L; Arya N; Curtright J; Fleming RA; Ho PT; Rowinsky EK
    J Clin Oncol; 2007 Aug; 25(24):3753-8. PubMed ID: 17704424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.
    Laheru D; Croghan G; Bukowski R; Rudek M; Messersmith W; Erlichman C; Pelley R; Jimeno A; Donehower R; Boni J; Abbas R; Martins P; Zacharchuk C; Hidalgo M
    Clin Cancer Res; 2008 Sep; 14(17):5602-9. PubMed ID: 18765554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
    Van Cutsem E; Verslype C; Beale P; Clarke S; Bugat R; Rakhit A; Fettner SH; Brennscheidt U; Feyereislova A; Delord JP
    Ann Oncol; 2008 Feb; 19(2):332-9. PubMed ID: 17986625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
    Jiang Y; Mackley HB; Kimchi ET; Zhu J; Gusani N; Kaifi J; Staveley-O'Carroll KF; Belani CP
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):205-10. PubMed ID: 24908435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.
    Díaz-Rubio E; Evans TR; Tabemero J; Cassidy J; Sastre J; Eatock M; Bisset D; Regueiro P; Baselga J
    Ann Oncol; 2002 Apr; 13(4):558-65. PubMed ID: 12056706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes.
    Kellokumpu-Lehtinen PL; Sunela K; Lehtinen I; Joensuu H; Sjöström-Mattson J;
    Clin Breast Cancer; 2006 Dec; 7(5):401-5. PubMed ID: 17239265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.
    Saif MW; Sarantopoulos J; Patnaik A; Tolcher AW; Takimoto C; Beeram M
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1565-73. PubMed ID: 21547572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
    Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
    Villalona-Calero MA; Weiss GR; Burris HA; Kraynak M; Rodrigues G; Drengler RL; Eckhardt SG; Reigner B; Moczygemba J; Burger HU; Griffin T; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 1999 Jun; 17(6):1915-25. PubMed ID: 10561233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer.
    Kordes S; Richel DJ; Klümpen HJ; Weterman MJ; Stevens AJ; Wilmink JW
    Invest New Drugs; 2013 Feb; 31(1):85-91. PubMed ID: 22367239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
    Lam ET; O'Bryant CL; Basche M; Gustafson DL; Serkova N; Baron A; Holden SN; Dancey J; Eckhardt SG; Gore L
    Mol Cancer Ther; 2008 Dec; 7(12):3685-94. PubMed ID: 19074845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors.
    Albanell J; Montagut C; Jones ET; Pronk L; Mellado B; Beech J; Gascon P; Zugmaier G; Brewster M; Saunders MP; Valle JW
    Clin Cancer Res; 2008 May; 14(9):2726-31. PubMed ID: 18451238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.